RESMED, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 218.6 USD | -0.64% |
|
+2.22% | +27.06% |
ETFs positioned on ResMed, Inc.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.03% | 1,006 M€ | -.--% | - | |
| 0.03% | 414 M€ | +13.07% | - | |
| 0.02% | 29 M€ | -.--% | - | |
| 0.02% | 322 M€ | +13.88% | - | |
| 0.02% | 17 M€ | +5.25% | - | |
| 0.02% | 9 M€ | +11.05% | - | |
| 0.02% | 17 M€ | +3.40% | - | |
| 0.02% | 105 M€ | +4.03% | - | |
| 0.02% | 1 M€ | +3.03% | - | |
| 0.02% | 26 M€ | +16.85% | - | |
| 0.02% | 32 M€ | +2.69% | - | |
| 0.02% | 7 M€ | +0.11% | - | |
| 0.02% | 6 M€ | +3.89% | ||
| 0.01% | 34 M€ | +3.87% | - | |
| 0.01% | 12 M€ | +14.24% | - | |
| 0.01% | 2 M€ | +3.16% | - | |
| 0.01% | 756 M€ | +0.82% | - | |
| 0.01% | 8 M€ | +1.17% | - | |
| 0.01% | 54 M€ | +1.01% | - |
ResMed, Inc. specializes in designing, manufacturing and marketing respiratory disorders diagnosis, treatments and management (primarily sleep respiratory disorders). Net sales break down by family of products as follows:
- medical devices (50.4%);
- masks (37.9%);
- software as a service (11.7%).
At the end of June 2021, the group had 6 production sites located in the United States (2), Australia, China, Singapore and Malaysia.
The United States accounts for 61.4% of net sales.
Calendar
2024-07-31
- Q4 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
218.6
USD
Average target price
216.6
USD
Spread / Average Target
-0.88%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +27.06% | 32.11B | |
| +12.15% | 227B | |
| +14.90% | 197B | |
| +18.22% | 141B | |
| +29.15% | 110B | |
| +0.53% | 64.15B | |
| +16.92% | 53.72B | |
| +6.33% | 51.75B | |
| +10.93% | 45.2B | |
| +5.87% | 37.37B |
- Stock Market
- Equities
- RMD Stock
- Funds and ETFs ResMed, Inc.
